Christian Waage 4

What Happened

• Christian Waage, EVP, Technical Operations & Administration at Gossamer Bio, did not sell stock but participated in a one-time repricing of outstanding stock options. On March 19, 2026 the company cancelled/surrendered multiple existing option awards (dispositions to the issuer) totaling 2,065,584 option shares and simultaneously granted replacement/repriced option awards in the same aggregate amount.
• The repriced options have a reduced per-share exercise price of $0.45 (effective March 19, 2026). If exercised in full at that price, the aggregate exercise cost would be about $929,513. The filing shows these as derivative transactions (options), not open-market stock trades.

Key Details

• Transaction date: March 19, 2026; Form 4 filed March 20, 2026 (timely filing).
• Options surrendered and regranted: 2,065,584 derivative shares in total (multiple tranches listed on the Form 4).
• New exercise price: $0.45 per share for the repriced options (per footnote F1).
• Shares owned after transaction: Not specified in the filing.
• Plan and vesting: Awards issued under the 2019 Incentive Award Plan; vesting schedule and term otherwise unchanged and remain subject to continued service (footnote F2).
• Nature of transaction: A modification/repricing of existing options (disposition of old awards and grant of repriced awards), not a cash sale or market purchase.

Context

• This is a corporate option repricing — the company reduced exercise prices on certain outstanding options to preserve their economic value; it’s not an indicator of immediate buying or selling by the insider.
• For retail investors: repricings affect potential future dilution and incentive alignment but do not involve immediate stock transfers or proceeds to the insider unless and until options are exercised and shares sold.